🇺🇸 FDA

Intelligence · Clinical Pipeline

LIGAND PHARMACEUTICALS Pipeline

All ClinicalTrials.gov programs at LIGAND PHARMACEUTICALS — phase, modality, and trial IDs.

Programs
34

Quick answer

LIGAND PHARMACEUTICALS has 34 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

  1. Intravenous Carbamazepine (IV CBZ)

    LIGAND PHARMACEUTICALS INC

    Epilepsy

    phase 3 small molecule completed

    1 trial

  2. Targretin Gel 1%

    LIGAND PHARMACEUTICALS INC

    Alopecia Areata

    phase 3 small molecule completed

    1 trial

  3. lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Osteoporosis

    phase 3 small molecule completed

    3 trials

  4. Alitretinoin

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    2 trials

  5. Aplindore

    LIGAND PHARMACEUTICALS INC

    Restless Legs Syndrome

    phase 2 small molecule completed

    1 trial

  6. Aplindore

    LIGAND PHARMACEUTICALS INC

    Early Stage Parkinson's Disease

    phase 2 small molecule completed

    1 trial

  7. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Lung Cancer

    phase 2 small molecule completed

    1 trial

  8. Bexarotene

    LIGAND PHARMACEUTICALS INC

    Sarcoma, Kaposi

    phase 2 small molecule completed

    1 trial

  9. Bexarotene (targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule terminated

    1 trial

  10. Bexarotene 1% gel

    LIGAND PHARMACEUTICALS INC

    Parapsoriasis

    phase 2 small molecule terminated

    1 trial

  11. Bexarotene/NBUVB vs placebo NBUVB

    LIGAND PHARMACEUTICALS INC

    Psoriasis

    phase 2 small molecule completed

    1 trial

  12. Budesonide

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  13. Budesonide + Azelastine

    LIGAND PHARMACEUTICALS INC

    Seasonal Allergic Rhinitis

    phase 2 small molecule completed

    1 trial

  14. CE-Iohexol

    LIGAND PHARMACEUTICALS INC

    Contrast-induced Nephropathy

    phase 2 small molecule terminated

    1 trial

  15. LGD-6972-5 mg

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  16. Lasofoxifene

    LIGAND PHARMACEUTICALS INC

    Bone Loss

    phase 2 small molecule completed

    1 trial

  17. MB07133 300mg/m2/day

    LIGAND PHARMACEUTICALS INC

    Hepatocellular Carcinoma

    phase 2 small molecule completed

    1 trial

  18. MB07803

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 2 small molecule completed

    1 trial

  19. MB07811

    LIGAND PHARMACEUTICALS INC

    Hypercholesterolemia

    phase 2 small molecule terminated

    1 trial

  20. PS433540

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

  21. bexarotene

    LIGAND PHARMACEUTICALS INC

    Cutaneous T-Cell Lymphoma

    phase 2 small molecule completed

    1 trial

  22. bexarotene

    LIGAND PHARMACEUTICALS INC

    Breast Cancer

    phase 2 small molecule completed

    1 trial

  23. denileukin diftitox

    LIGAND PHARMACEUTICALS INC

    Drug/Agent Toxicity by Tissue/Organ

    phase 2 mab completed

    1 trial

  24. erlotinib and bexarotene

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    phase 2 small molecule completed

    1 trial

  25. irbesartan

    LIGAND PHARMACEUTICALS INC

    Hypertension

    phase 2 small molecule completed

    1 trial

  26. Bexarotene (Targretin®)

    LIGAND PHARMACEUTICALS INC

    Advanced, Malignant Aerodigestive Tract Tumor (Lung, Head and Neck and Esophagus)

    phase 1 small molecule completed

    1 trial

  27. LGD-6972

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus

    phase 1 small molecule completed

    2 trials

  28. LGD-6972 Solution

    LIGAND PHARMACEUTICALS INC

    Type 2 Diabetes Mellitus (T2DM)

    phase 1 small molecule completed

    1 trial

  29. NCO-48 Fumarate

    LIGAND PHARMACEUTICALS INC

    Hepatitis B

    phase 1 small molecule completed

    1 trial

  30. NCO-48 Fumarate 4 mg

    LIGAND PHARMACEUTICALS INC

    Chronic Hepatitis B

    phase 1 small molecule completed

    1 trial

  31. Ramipril tablet 10 mg

    LIGAND PHARMACEUTICALS INC

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  32. Ramipril/Hydrochlorothiazide tablet 10 mg/25 mg

    LIGAND PHARMACEUTICALS INC

    Bioequivalence

    phase 1 small molecule completed

    1 trial

  33. ONTAK (denileukin difitox, DAB389IL-2)

    LIGAND PHARMACEUTICALS INC

    Lymphoma, T-Cell, Cutaneous

    approved small molecule completed

    1 trial

  34. erlotinib (Tarceva) and bexarotene (Targretin)

    LIGAND PHARMACEUTICALS INC

    Carcinoma, Non-small-cell Lung

    small molecule completed

    1 trial

Frequently asked questions

How many pipeline programs does LIGAND PHARMACEUTICALS have?

34 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This hub lists all published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.